RELIEF Therapeutics Holding AG
Developing and commercializing novel therapies for rare and ultra-rare diseases.
RLF | SW
Overview
Corporate Details
- ISIN(s):
- CH1251125998
- LEI:
- 506700IT19260EVD7916
- Country:
- Switzerland
- Address:
- avenue de Sécheron 15, 1202 Genève
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
RELIEF Therapeutics Holding AG is a commercial-stage biopharmaceutical company focused on developing and commercializing novel, patent-protected therapies for rare and ultra-rare diseases with high unmet medical needs. The company's mission is to advance its pipeline of therapeutic candidates to provide patients with treatments that can significantly improve their condition and quality of life. Its strategy involves advancing clinical programs, such as its candidate for Epidermolysis Bullosa (RLF-TD011), and pursuing strategic transactions, including partnerships and business combinations, to accelerate development and market access for its products.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-25 07:00 |
Regulatory Filings
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook …
|
English | 11.1 KB | ||
| 2025-11-25 01:00 |
M&A Activity
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook …
|
English | 8.4 KB | ||
| 2025-11-14 18:20 |
AGM Information
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
|
English | 12.9 KB | ||
| 2025-11-14 01:00 |
AGM Information
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
|
English | 10.3 KB | ||
| 2025-10-29 07:00 |
Regulatory Filings
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Stud…
|
English | 12.2 KB | ||
| 2025-10-29 01:00 |
Regulatory Filings
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Stud…
|
English | 10.0 KB | ||
| 2025-10-24 06:59 |
Pre-Annual General Meeting Information
Relief Therapeutics Convenes Extraordinary General Meeting
|
English | 12.0 KB | ||
| 2025-10-24 02:00 |
Pre-Annual General Meeting Information
Relief Therapeutics Convenes Extraordinary General Meeting
|
English | 9.5 KB | ||
| 2025-10-08 07:00 |
M&A Activity
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreemen…
|
English | 19.8 KB | ||
| 2025-10-08 02:00 |
M&A Activity
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreemen…
|
English | 17.3 KB | ||
| 2025-08-14 07:00 |
Report Publication Announcement
Relief Therapeutics Publishes 2025 Half-Year Report
|
English | 9.0 KB | ||
| 2025-08-14 02:00 |
Report Publication Announcement
Relief Therapeutics Publishes 2025 Half-Year Report
|
English | 6.8 KB | ||
| 2025-08-11 07:00 |
Report Publication Announcement
Relief Therapeutics Advances Publication of 2025 Half-Year Report
|
English | 6.9 KB | ||
| 2025-08-11 02:00 |
Report Publication Announcement
Relief Therapeutics Advances Publication of 2025 Half-Year Report
|
English | 4.8 KB | ||
| 2025-07-29 07:00 |
M&A Activity
Relief Therapeutics Announces Proposed Business Combination with NeuroX, succes…
|
English | 15.9 KB |
Automate Your Workflow. Get a real-time feed of all RELIEF Therapeutics Holding AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for RELIEF Therapeutics Holding AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for RELIEF Therapeutics Holding AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
